title: Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients.
abstract: We reviewed the clinical findings in 55 patients with cerebellar degeneration associated with the anti-Yo antibody (an anti-Purkinje cell antibody identified in this study by histochemistry and Western blot). The patients were all women, 26 to 85 years old. Fifty-two of them proved to have malignancies, almost exclusively breast or gynecologic cancers and usually confined to the involved organs and local lymph nodes. One woman had adenocarcinoma of the lung, and in three no malignancy has yet been identified. In 34 of 52 patients with cancer, the neurologic syndrome preceded the diagnosis of cancer and in many led to that diagnosis. Patients subacutely developed a pancerebellar disorder that was substantially disabling in most, with 37 of 48 assessable patients being unable to walk or sit unassisted. Laboratory evaluation revealed lymphocytic pleocytosis in 35 patients, with eventual cerebellar atrophy on imaging studies in seventeen. The disabling neurologic syndrome generally did not respond to treatment, but the cancer was often successfully treated. The presence of the anti-Yo antibody in patients with cerebellar symptoms warrants an aggressive approach to diagnosis and treatment of the underlying cancer, as many are curable at the time neurologic symptoms develop.
authors.affiliation: Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: K
authors.initials: K
authors.lastname: Peterson
authors.forename: M K
authors.initials: MK
authors.lastname: Rosenblum
authors.forename: H
authors.initials: H
authors.lastname: Kotanides
authors.forename: J B
authors.initials: JB
authors.lastname: Posner
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000032:analysis*; D001324:Autoantigens; D002525:Cerebellar Cortex / Q000473:pathology; D002526:Cerebellar Diseases / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy; D002555:Cerebrospinal Fluid / Q000166:cytology / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000276:immunology*; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000276:immunology*; D009369:Neoplasms / Q000473:pathology; D009419:Nerve Tissue Proteins; D009420:Nervous System / Q000503:physiopathology; D010257:Paraneoplastic Syndromes / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy; D014057:Tomography, X-Ray Computed
chemical_list: D000906:Antibodies; D001324:Autoantigens; C063762:CDR1 protein, human; C095184:CDR2 protein, human; D004268:DNA-Binding Proteins; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins